Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA501 vs Tresiba in Type 2 Diabetes Mellitus
CTR20221898Phase 3Completed
- Sponsor
- Chongqing Chen'an Biopharmaceutical
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Chongqing Chen'an Biopharmaceutical. Started Aug 2022; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20221898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221898.